Notes
1. Kumar A, Wallner EI, Carone FA, Scarpelli DG, Kanwar YS. Int J Dev Biol. 1997;41:643–653.
2.
Méchali M, Gusse M, Vriz S, et al.
Proto-oncogenes and embryonic development,
Biochimie. 1988 Jul;70(7):895–898.
3. Kiessling AA. Expression of proto-oncogenes in mammalian gametes and embryos. Technol Infertil. 1993;119–133.
4. Rowley JD. Nonrandom chromosomal changes in human malignant cells. In: Sparkes RS, Comings DE, Fox CF, eds.
Moleular Human Cytogenetics.
New York: Academic Press:457–482.
5. Van Oijen MG, Slootweg PJ. Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res. June 2000;6:2138–2145.
6. Trosko
JE, Chang CC, Upham BL, Tai MH. Ignored
hallmarks of carcinogenesis: stem cells and cell-cell communication.
Ann NY Acad Sci. 2004 Dec.;1028:192–201.
7. Pethig R, Gascoyne PRC, McLaughlin JA, Szent-Györgyi A. Ascorbate-quinone interactions: Electrochemical, free radical, and cytotoxic properties. Proc Natl Acad Sci U S A. January 1983;80:129–132.
8. Boros LG, Lapis K, Szende B, et al. Wheat germ extract decreases glucose uptake and RNA ribose formation but increases fatty acid synthesis in MIA pancreatic adenocarcinoma cells. Pancreas. 2001;23(2):141–147.
9. Comín-Anduix B, Boros LG, Marin S, et al. Fermented wheat germ extract inhibits glycolysis/pentose cycle enzymes and induces apoptosis through poly(ADP-ribose) polymerase activation in Jurkat T-cell leukemia tumor cells. J Biol Chem. 2002;277(48):46408–46414.
10. Ibid.
11. Jakab F, Shoenfeld Y, Balogh A, et al. A medical nutriment has supportive value in the treatment of colorectal cancer. Br J Cancer. 2003;89:465–469.
12. Barabás J, Németh Z. The opinion of Hungarian Association of Oral and Maxillofacial Surgeons (Magyar Arc-, Állcsont- és Szájsebészeti Társaság) on the justification of supportive treatment of patients with tumorous diseases of the oral cavity. Hung Med J. 2006;147(35):1709–1711.
13. Demidov LV, Manziuk LV, Kharkevitch GY, Pirogova NA, Artamonova EV. Adjuvant fermented wheat germ extract (Avemar) nutraceutical improves survival of high-risk skin melanoma patients: a randomized, pilot, phase II clinical study with a 7-year follow-up. Cancer Biother Radiopharm. 2008;23(4):477–482.
Author
0 Comments